Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troriluzole in Obsessive Compulsive Disorder
NCT04641143Phase 3Completed
- Sponsor
- Biohaven Ltd.
- Start
- Dec 2020
- Primary completion
- Oct 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Troriluzole with Placebo (2 arms). Primary endpoint: Yale-Brown Obsessive Compulsive Scale Total at 10 weeks. Started Dec 2020; status: completed.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT04641143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641143.